Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

NCT01351038 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
43
Enrollment
OTHER
Sponsor class

Stopped REAL trial showed a significant difference in OS for reduced EOX and standard EOX

Conditions

Interventions

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators